Innate Pharma SA - Product Pipeline Review - 2015

Published: Jul, 2015 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Innate Pharma SA - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Innate Pharma SA - Product Pipeline Review - 2015', provides an overview of the Innate Pharma SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Innate Pharma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Innate Pharma SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Innate Pharma SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Innate Pharma SA's pipeline products

Reasons to buy

- Evaluate Innate Pharma SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Innate Pharma SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Innate Pharma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Innate Pharma SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Innate Pharma SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Innate Pharma SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Innate Pharma SA Snapshot 5
Innate Pharma SA Overview 5
Key Information 5
Key Facts 5
Innate Pharma SA - Research and Development Overview 6
Key Therapeutic Areas 6
Innate Pharma SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Innate Pharma SA - Pipeline Products Glance 13
Innate Pharma SA - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Innate Pharma SA - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Innate Pharma SA - Drug Profiles 17
IPH-2201 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
IPH-33 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
IPH-4102 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
IPH-43 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibody for Cancer and Inflammation 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibody 1 for Cancer 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody 2 for Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody to Inhibit NKp46 for Cancer and Inflammation 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Innate Pharma SA - Pipeline Analysis 26
Innate Pharma SA - Pipeline Products by Target 26
Innate Pharma SA - Pipeline Products by Route of Administration 27
Innate Pharma SA - Pipeline Products by Molecule Type 28
Innate Pharma SA - Pipeline Products by Mechanism of Action 29
Innate Pharma SA - Recent Pipeline Updates 30
Innate Pharma SA - Dormant Projects 32
Innate Pharma SA - Discontinued Pipeline Products 33
Discontinued Pipeline Product Profiles 33
Autologous Gamma Delta T Lymphocytes 33
IPH-1101 33
IPH-1201 33
IPH-2101 34
IPH-3102 34
IPH-3201 34
IPH-4101 34
IPH-4201 34
Innate Pharma SA - Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables

Innate Pharma SA, Key Information 5
Innate Pharma SA, Key Facts 5
Innate Pharma SA - Pipeline by Indication, 2015 7
Innate Pharma SA - Pipeline by Stage of Development, 2015 9
Innate Pharma SA - Monotherapy Products in Pipeline, 2015 10
Innate Pharma SA - Out-Licensed Products in Pipeline, 2015 11
Innate Pharma SA - Out-Licensed Products/ Combination Treatment Modalities, 2015 12
Innate Pharma SA - Phase II, 2015 13
Innate Pharma SA - Phase I, 2015 14
Innate Pharma SA - Preclinical, 2015 15
Innate Pharma SA - Discovery, 2015 16
Innate Pharma SA - Pipeline by Target, 2015 26
Innate Pharma SA - Pipeline by Route of Administration, 2015 27
Innate Pharma SA - Pipeline by Molecule Type, 2015 28
Innate Pharma SA - Pipeline Products by Mechanism of Action, 2015 29
Innate Pharma SA - Recent Pipeline Updates, 2015 30
Innate Pharma SA - Dormant Developmental Projects,2015 32
Innate Pharma SA - Discontinued Pipeline Products, 2015 33
Innate Pharma SA, Subsidiaries 35